Department of Gynaecology and Obstetrics, University of Wuerzburg, Josef-Schneider-Strasse 4, Wuerzburg, 97080, Germany.
J Cancer Res Clin Oncol. 2010 Feb;136(2):219-25. doi: 10.1007/s00432-009-0652-y. Epub 2009 Aug 5.
Metabolic dependence on glucose utilisation has been described for different tumours characterised by activation of Akt, upregulation of GLUT1, M2PK and TKTL1. To date, however, little is known about glucose metabolism in breast cancer tissue.
We analysed 55 breast cancer specimens, 26 adjacent ductal carcinomas in situ (DCIS) and 23 adjacent normal breast tissues for expression of glycolytic markers by immunohistochemistry.
We found expression of pAkt in 49%, GLUT1 in 25%, M2PK in 68% and TKTL1 in 31% of the tumours investigated. Expression of pAkt and Her2neu are positively correlated with borderline significance (P = 0.055). Expression of pAkt, GLUT1 and TKTL1 were higher in breast cancer and DCIS than in normal tissue. Surprisingly, M2PK expression was highest in normal breast tissue.
We found a glycolytic phenotype in a high percentage of breast cancer samples. Inhibition of glycolysis might evolve as a future option for breast cancer therapy.
在 Akt 激活、GLUT1、M2PK 和 TKTL1 上调的不同肿瘤中，已经描述了对葡萄糖利用的代谢依赖性。然而，迄今为止，人们对乳腺癌组织中的葡萄糖代谢知之甚少。
我们通过免疫组织化学分析了 55 例乳腺癌标本、26 例相邻导管原位癌（DCIS）和 23 例相邻正常乳腺组织中糖酵解标志物的表达。
我们发现所研究的肿瘤中有 49%表达 pAkt、25%表达 GLUT1、68%表达 M2PK 和 31%表达 TKTL1。pAkt 和 Her2neu 的表达呈正相关（P=0.055）。pAkt、GLUT1 和 TKTL1 在乳腺癌和 DCIS 中的表达高于正常组织。令人惊讶的是，M2PK 的表达在正常乳腺组织中最高。
我们在很大比例的乳腺癌样本中发现了糖酵解表型。抑制糖酵解可能会成为乳腺癌治疗的未来选择。
